Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
Stopped early · Not applicable
Conditions studied: Diabetic Foot Ulcer, Venous Leg Ulcer
In brief
In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care. In participants with venous leg ulcers (VLUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with living cellular skin substitute (Apligraf®)
Key facts
- Study ID
- NCT04927702
- Run by
- Acera Surgical, Inc.
- People needed
- 48
- Starts
- 2021-07-19
- Expected to finish
- 2024-08-01
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- ILD Research Center — Vista, California, United States
- University of Florida - Jacksonville — Jacksonville, Florida, United States
- Barry University — Miami Beach, Florida, United States
- Rush University Medical Center — Chicago, Illinois, United States
- Boston Medical Center — Boston, Massachusetts, United States
- Gundersen Health System — La Crosse, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.